Heart Failure

An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

Early follow-up in patients with COPD led to lower rates of readmissions at 90 days, while patients with CHF saw lower 90-day mortality.

Women show significantly lower risk of first, recurrent life-threatening VTA events than men, while it is more pronounced in patients with NICM.

Rivaroxaban monotherapy was associated with a 38% lower risk of total cardiovascular and bleeding events.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

Both exogenous hyperthyroidism and exogenous hypothyroidism were associated with increased risk of cardiovascular mortality.

Aortic sclerosis, trace or mild aortic regurgitation, and mild mitral regurgitation each had significant associations with CV risk.

The study authors used data from Medicare beneficiaries who survived a heart attack between 1995 and 2019.

Investigators observed no reduction in readmission or mortality in a remote monitoring program with incentives for patients previously hospitalized for HF.

The rate of long-term survival after 10 years in patients surviving the initial hospital stay after OHCA was between 62% and 64%.

Data show 7 risk factors, many potentially modifiable, accounted for 85% of the risk of first AMI in young women and men.

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.

Study investigators used data from midlife checkpoints and late life checkpoints for participants without heart failure.

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

Data show 80% of included patients had an increase of more than 20 points in Kansas City Cardiomyopathy Questionnaire summary scores.

No evidence of lower Lp(a)-associated risks in hormone therapy users versus nonusers was observed.

Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.